As described earlier, severe COVID-19 may cause ARDS that can result in microvascular thrombosis, extensive thrombin generation and fibrin formation, because of mass upregulation of inflammatory cytokines and leukocytes.90In reports of its use in severe infection case, an initial improvement was observed after tPA infusion.91, 92, 93Antiplatelet therapies are also potentially promising in managing COVID-19 associated thrombosis. This evidence concerns the gene PLAT and COVID-19.